Please assess the completion status of the following clinical trial:

Trial Title: ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian women aged 18 years and older with proven HPV-associated CIN 2/3~* Colposcopy with fully visible transformation zone and lesion~* Safe Contraception~* Signed Informed Consent~* Negative urine pregnancy test~* Able to communicate well with the investigator, to understand and comply with the requirements of the study~* Signed the written informed consent~Exclusion Criteria:~* Women who are pregnant or lactating or become pregnant during the conduct of the study~* Symptoms of a clinically relevant illness in the 3 weeks before the first study day~* History of hypersensitivity to the trial drug or to drugs with a similar chemical structure~* Participating in another clinical trial within 30 days~* Malignancy~* Immunosuppression (medication, illness)~* HIV- or Hepatitis infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Imiquimod (Type: ACTIVE_COMPARATOR): topical therapy for 16 weeks with imiquimod containing therapy
- Placebo (Type: PLACEBO_COMPARATOR): topical therapy for 16 weeks with a placebo containing vaginal suppository

Based on this trial design, predict the completion outcome and termination type (if applicable).